US 2003-514692P

WO 2004-US32918

OS GI Ρ

W

CASREACT 142:392179; MARPAT 142:392179

20031027

20041004

(FILE 'HOME' ENTERED AT 19:58:24 ON 18 JUN 2008) FILE 'REGISTRY' ENTERED AT 20:02:04 ON 18 JUN 2008 L1STRUCTURE UPLOADED L2 1 S L1 SSS L3 27 S L1 SSS FULL FILE 'CAPLUS' ENTERED AT 20:02:44 ON 18 JUN 2008 L41 S L3 => d bib abs ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN L42005:324121 CAPLUS ΑN 142:392179 DNTΙ Preparation of acyloxydiphenylbutenylcinnamates as estrogen receptor modulator prodrugs. ΙN Eaddy, John Fred, III; Heyer, Dennis; Katamreddy, Subba Reddy; Martin, Michael Tolar; McClure, Michael Scott; Randhawa, Amarjit Sab; Samano, Vicente; Ray, John Albert PASmithkline Beecham Corporation, USA PCT Int. Appl., 78 pp. SO CODEN: PIXXD2 Patent DT LA English FAN.CNT 1 DATE PATENT NO. KIND APPLICATION NO. DATE ____ _____ WO 2005033056 A2 20050414 WO 2004-US32918 PΙ 20041004 А3 20050623 WO 2005033056 AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG EP 1692127 Α2 20060823 EP 2004-809876 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR US 20070111971 20070517 US 2006-575038 Α1 20060406 PRAI US 2003-509678P Ρ 20031008

AB Title compds. (I; R1 = ACO, PO3H2; A = alkyl, aryl, heteroaryl, cycloalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkyl, heterocyclylalkyl), were prepared Thus, I (R1 = H) (preparation given) and Et3N in THF at 5° were treated with propionyl chloride in THF followed by stirring for 1 h to give 64% I (R1 = EtCO). The latter orally in rats showed 86.6% bioavailability, vs. 5.7% for I (R1 = H).

=>